1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - General
Biogen Inc.

Biogen Inc.

IDP.DE
Biogen Inc.DE flagDeutsche Börse
165.68
EUR
+4.14
- -
24.46BMarket Cap
Biogen Inc.
IDP.DE
(Deutsche Börse)

Recent

price

165.68

P/E

ratio

- -

div

yld

- -

ROIC.AI

2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
FRC
18.69
20.83
23.18
29.26
41.05
46.66
52.42
57.73
65.66
76.85
83.56
73.65
70.02
67.97
66.46
67.51
67.69
Revenue per Share
3.98
5.09
5.8
7.86
12.42
15.37
16.95
11.94
21.62
31.47
24.86
10.44
20.97
8.02
11.21
8.83
9.35
Basic EPS, GAAP
5.75
6.27
6.83
-4.91
11.11
14.14
17.67
12.17
25.87
34.25
22.86
22.43
7.85
8.54
17.28
13.44
15.78
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
7.42
12.82
18.86
26.8
39.28
52.92
69.01
74.37
79.34
87.95
86.86
93.31
113.33
121.82
132.28
140.29
142.18
Book Value per Share
10.03
15.15
17.36
12.3
21.26
11.38
21.3
19.22
20.52
21.67
11.43
19.97
39.84
1.5
3.75
17.66
21.18
Tangible Book Value per Share
252
242
238
237
236
231
218
213
205
187
161
149
145
145
146
146
147
Basic Weighted Avg Shares
4,716
5,049
5,516
6,932
9,703
10,764
11,449
12,274
13,453
14,378
13,445
10,982
10,173
9,836
9,676
9,891
9,937
Sales/Revenue/Turnover
33.27
35.25
33.33
35.92
40.37
46.59
49.39
45.05
44.61
48.93
33.07
25.57
28.52
18.79
23.57
24.96
23.18
Operating Margin (%)
356
359
366
532
688
600
683
1,081
650
465
457
488
518
495
673
780
801
Depreciation Expense
1,005
1,234
1,380
1,862
2,935
3,547
3,703
2,539
4,431
5,888
4,001
1,556
3,047
1,161
1,632
1,293
1,372
Net Income, GAAP
26.94
25.98
25.37
24.23
25.08
24.37
25.08
47.94
24.16
16.25
19.66
3.01
17.62
10.43
14.37
16.94
15.47
Effective Tax Rate (%)
21.31
24.45
25.02
26.86
30.25
32.95
32.34
20.69
32.93
40.96
29.76
14.17
29.95
11.81
16.87
13.07
13.81
Profit Margin (%)
1,490
2,063
1,587
1,427
2,317
4,123
5,312
4,505
4,346
3,518
3,145
3,558
6,518
3,425
1,928
5,625
6,192
Working Capital
1,066
1,061
687
592
580
6,522
6,513
5,935
5,936
4,872
7,828
6,604
6,614
7,188
4,882
6,577
6,562
LT Debt
5,449
6,427
6,964
8,621
10,814
9,375
12,129
12,598
13,032
13,339
10,686
10,960
13,388
14,799
16,716
18,257
18,652
Total Equity
16.29
18.61
17.59
21.54
28
27.41
24.22
15.36
24.18
30.37
18.59
14.57
12.26
7.76
8.44
8.4
7.86
Return on Invested Capital (%)
42.65
33.6
28.71
30
35.08
24.98
19.37
11.72
20.67
26.87
18.47
7.52
14.94
5.75
7.26
5.72
5.99
Return on Capital (%)
68.35
49.58
36.35
34.37
37.55
33.01
27.15
16.44
27.63
36
26.29
11.16
20.06
6.81
8.85
6.49
6.8
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
ST Debt
- -
- -
- -
LT Borrowings
6,285
6,287
6,288
LT Finance Leases
305
290
273
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
147
147
148
Market Capitalization
20,100
25,796
26,212

Working Capital

FRC

•

in mil. unless spec.
Sep'25
Dec'25
Mar'26
Total Current Assets
8,937
8,974
9,190
Cash, Cash Equivalents & STI
3,960
3,816
4,283
Accounts Receivable, Net
1,850
1,867
1,790
Inventories
2,209
2,168
1,949
Total Current Liabilities
3,290
3,349
2,999
Payables & Accruals
2,890
2,974
2,806
ST Debt
- -
- -
- -
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
7.66%
11.49%
9.22%
Free Cash Flow
8.37%
3.04%
-21.72%
Net Income, GAAP
4.09%
-1.48%
-20.79%
Sales/Revenue/Turnover
-0.48%
-5.68%
2.22%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2,290
2,465
2,466
2,455
9,676
2025
2,431
2,646
2,535
2,279
9,891
2026
2,478
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
2.71
4.01
2.67
1.83
11.21
2025
1.65
4.33
- -
-0.33
8.83
2026
2.17
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
Similar Companies
Cipla Limited (CIPLA.BO)
Hunan Jingfeng Pharmaceutical Co.,Ltd. (000908.SZ)
Bayer AG (BAYRY)
Oscotec Inc. (039200.KQ)
Jiangsu Hengrui Medicine Co., Ltd. (600276.SS)
Chugai Pharmaceutical Co., Ltd. (CHGCF)
Business
Biogen Inc. (IDP.DE) develops, markets, and manufactures therapies for neurological, rare, and hemophilia diseases. The company offers a portfolio of products including Aduhelm (aducanumab) and Leqembi (lecanemab) for Alzheimer's disease; Vumerity (diroximel fumarate), Tecfidera (dimethyl fumarate), and Vraylar (cariprazine) for multiple sclerosis and related disorders; Spinraza (nusinersen) for spinal muscular atrophy; and Skyclarys (omaveloxolone) for Friedreich's ataxia; along with Eloctate and Alprolix for hemophilia A and B, and other biosimilars and gene therapies in development. Biogen operates in the biotechnology sector, targeting patients with neurodegenerative, neuromuscular, and hematologic conditions through partnerships with healthcare providers, hospitals, and specialty pharmacies worldwide. Founded in 1978 and headquartered in Cambridge, Massachusetts, the company maintains significant commercial presence in the United States, Europe, Asia-Pacific, and Latin America, with key subsidiaries including Biogen International GmbH in Switzerland and Biogen Japan Ltd. Recent major developments include the 2024 European Commission approval of Felzartamab for IgA nephropathy, a strategic licensing agreement with Ionis Pharmaceuticals for the ALS therapy BIIB115, and the divestiture of its hemophilia business to BioMarin Pharmaceutical in late 2023 to focus on core neurology pipeline; additionally, in 2025, Biogen announced expanded Phase 3 trials for zorevunersen in muscle atrophy and a collaboration with Sage Therapeutics on zuranolone for postpartum depression [ from previous searches, but adapted].